Connect Biopharma reports COPD trial results

• Connect Biopharma (NASDAQ:CNTB) reported preliminary Phase 2 results showing rademikibart reduced treatment failure in acute COPD exacerbations.
• The study showed an 81% reduction in treatment failure versus placebo through Week 4 (p=0.0122).
• Connect plans to seek FDA guidance on a potential Phase 3 development program for rademikibart in COPD.

Connect Biopharma (NASDAQ:CNTB) reported preliminary Phase 2 results showing that investigational rademikibart reduced treatment failure in adults with acute chronic obstructive pulmonary disease (COPD) exacerbations and type 2 inflammation.

The randomized, placebo-controlled study enrolled 159 adults and showed an 81% reduction in treatment failure with rademikibart compared with placebo through Week 4, with a p-value of 0.0122.

The study reported an 85% reduction in new moderate to severe exacerbations and a 100% reduction in emergency visits or hospital admissions for new exacerbations compared with placebo, while rescue inhaler use declined significantly during Weeks 2–7.

Rademikibart treatment also improved COPD symptoms at Week 2, while the improvement in forced expiratory volume in one second (FEV1), a lung function measurement, was 70 mL greater at Week 4 compared with placebo but did not reach statistical significance (p=0.1607).

Connect Biopharma reported no new safety signals, with adverse events and serious adverse events occurring less frequently in the rademikibart group than the placebo group, and stated it plans to seek FDA alignment on a Phase 3 program.